ACTRN12617001613392已完成4 期
Effect of liraglutide on weight loss in patients with inadequate weight loss following bariatric surgery: A Randomised Controlled Trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 20 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Patients will be considered for inclusion if they are 12-18 months post LAGB, have achieved a stable weight but have not achieved 12% total body weight loss; are 20-65 years of age. A Stable Weight” is defined as a weight that is consistent within a 4 kg range over a 3 month period.
排除标准
- •Patients will be excluded from this study if they: have hypersensitivity to liraglutide or any of its excipients; have a past history of GLP-1 analogue associated pancreatitis; will not accept the randomisation process; have a correctable mechanical issue with the LAGB that could explain the lack of weight loss; have a history of previous obesity surgery other than LAGB; have medical issues which contraindicate the application of either arm of the study such as acute myocardial infarction within the past 6 months, dementia, bulimia, active psychosis, concurrent experimental drug use, current pregnancy, lactation, illicit drug use, excessive alcohol intake, use of drugs known to affect body composition, cytotoxic drugs, internal malignancy, or major organ failure; have used a GLP-1 agonist in the previous 12 months; are unable to understand the risks, realistic benefits and compliance requirements of the interventions.
- •There has been an increase in thyroid cancer reported in rodent models that have utilised liraglutide 3.0 mg and whilst this has not been validated in humans, patients with a personal or family history of medullary thyroid cancer will be excluded. Pancreatitis has been identified as a potential side effect although no studies to date have confirmed this. Because of this concern patient who are at risk of pancreatitis for other reasons (drugs, excessive alcohol intake, known symptomatic gallstones) will be excluded. Nausea is an expected side effect of liraglutide 3.0 mg and it is possible that the gastric band will need to be deflated acutely if the nausea is severe and causes vomiting. Therefore, patients who reside more than one hour from the Clinic will be excluded. Tachycardia is an occasional side effect of liragulatide 3.0 mg with the mechanism currently unknown. Patients with known tachycardia will therefore be excluded. Patients with congestive heart failure NY-HA class III-IV or inflammatory bowel disease will be excluded.
研究者
相似试验
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeObesity(Prader-Willi syndrome)MedDRA version: 18.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-004415-37-FRovo Nordisk A/S60
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeEUCTR2014-004415-37-ITovo Nordisk A/S56
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeEUCTR2014-004415-37-NLovo Nordisk A/S60
已完成
3 期
Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period.weight management10003018ObesityNL-OMON47321ovo Nordisk6
进行中（未招募）
1 期
ifestyle induced weight loss and Liraglutide in the treatment of NASHon-alcoholic steatohepatitis (NASH)EUCTR2016-002045-36-GBniversity of Oxford, Clinical Trials and Research Governance50